Gold nanoparticles reduce inflammation in cerebral microvessels of mice with sepsis

Davide Di Bella1, João P. S. Ferreira1, Renee de Nazare O. Silva1, Cinthya Echem1, Aline Milan1, Eliana H. Akamine1, Maria H. Carvalho1 and Stephen F. Rodrigues1,2*

Abstract
Background: Sepsis is an emergency medical condition that can lead to death and it is defined as a life-threatening organ dysfunction caused by immune dysregulation in response to an infection. It is considered the main killer in intensive care units. Sepsis associated-encephalopathy (SAE) is mostly caused by a sepsis-induced systemic inflammatory response. Studies report SAE in 14–63% of septic patients. Main SAE symptoms are not specific and usually include acute impairment of consciousness, delirium and/or coma, along with electroencephalogram (EEG) changes. For those who recover from sepsis and SAE, impaired cognitive function, mobility and quality of life are often observed months to years after hospital discharge, and there is no treatment available today to prevent that. Inflammation and oxidative stress are key players for the SAE pathophysiology. Gold nanoparticles have been demonstrated to own important anti-inflammatory properties. It was also reported 20 nm citrate-covered gold nanoparticles (cit-AuNP) reduce oxidative stress. In this context, we tested whether 20 nm cit-AuNP could alleviate the acute changes caused by sepsis in brain of mice, with focus on inflammation. Sepsis was induced in female C57BL/6 mice by cecal ligation and puncture (CLP), 20 nm cit-AuNP or saline were intravenously (IV) injected 2 h after induction of sepsis and experiments performed 6 h after induction. Intravital microscopy was used for leukocyte and platelet adhesion study in brain, blood brain barrier (BBB) permeability carried out by Evans blue assay, cytokines measured by ELISA and real time PCR, cell adhesion molecules (CAMs) by flow cytometry and immunohistochemistry, and transcription factors, by western blotting.

Results: 20 nm cit-AuNP treatment reduced leukocyte and platelet adhesion to cerebral blood vessels, prevented BBB failure, reduced TNF- concentration in brain, and ICAM-1 expression both in circulating polymorphonuclear (PMN) leukocytes and cerebral blood vessels of mice with sepsis. Furthermore, 20 nm cit-AuNP did not interfere with the antibiotic effect on the survival rate of mice with sepsis.

Conclusions: Cit-AuNP showed important anti-inflammatory properties in the brain of mice with sepsis, being a potential candidate to be used as adjuvant drug along with antibiotics in the treatment of sepsis to avoid SAE

Keywords: Gold nanoparticles, Septic encephalopathy, Mice, Cell adhesion molecules

*Correspondence: stephen.rodrigues@usp.br
1 Laboratory of Hypertension, Diabetes and Vascular Biology, Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 1524, ICB I, sala 205, 2º andar, Butanta, 05508-900 Sao Paulo, Brazil
Full list of author information is available at the end of the article

© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
is even higher in poor countries [2–4]. Several organs are dramatically affected by sepsis, such as liver, kidneys, lung, gut, and brain [5].

Brain dysfunction during sepsis is widely known as sepsis associated-encephalopathy (SAE) and is mostly caused by a sepsis-induced systemic inflammatory response. Epidemiologically, studies report SAE in 14–63% of septic patients and suggest the large variability observed is due to differences in sepsis severity, SAE diagnostic criteria and individual patient characteristics [6, 7]. Main SAE symptoms are not specific and usually include acute impairment of consciousness, delirium and/or coma, along with electroencephalogram (EEG) changes [8, 9]. Other signs may include hallucinations, disturbances of sleep-wake cycle and agitation. Then, SAE diagnosis is mainly performed by exclusion in all patients with delirium of unknown origin [9]. Poor prognosis along with increasing economic burden are frequently associated with SAE [10–13]. For those who recover from sepsis and SAE, impaired cognitive function, mobility and quality of life are often observed months to years after hospital discharge [14, 15], and there is no treatment available today to prevent that.

Inflammation and oxidative stress are key players for the SAE pathophysiology [16]. Two main sites contribute to sense systemic inflammation in brain when the blood brain barrier (BBB) is still intact: the circumventricular organs (CVO) and the vagus nerve [17–19]. Several receptors involved in the immune system function have been reported in the CVO of animals, for instance: interleukin 1 receptor (IL-1R), IL-6R, tumor necrosis factor alpha (TNFα) receptor, Toll-like receptor 4 (TLR4) and cluster of differentiation 14 (CD14) [20, 21]. TLR4 and CD14 are receptors that recognize the lipopolysaccharide (LPS) endotoxin, a component of the cell wall of Gram-negative bacteria [17, 22]. LPS leads to synthesis and release of pro-inflammatory mediators such as TNFα, IL-1β, IL-6, and nitric oxide (NO) [22, 23]. These mediators play important roles in endotoxin-induced responses in brain such as fever, anorexia, sleep, behavioral and neuroendocrine changes [19, 24]. Along with the CVO, the vagus nerve senses peripheral inflammation through its axonal cytokine receptors. The signal is then transmitted to the central nervous system (CNS), particularly to the nucleus of the solitary tract, which controls the baroreflex and is connected to autonomic structures and hypothalamus [25]. Vagotomy prevents fever induced by endotoxin, TNF or IL-1. Progression of sepsis results in BBB failure and further cerebral inflammatory injury [26]. Concomitantly injected in mice with antibiotic treatment, 20 nm cit-AuNP reduces leukocyte adhesion to vascular endothelial cells after surgery-induced leukocyte chemotaxis in mesentery of Wistar rats [32]. The same way, it was demonstrated that 15 to 20 nm cit-AuNP reduce the number of leukocytes in LPS-stimulated peritoneum or in the collagen type II immunization-induced knee joint lesion in Wistar rats [33–35]. Anti-inflammatory action of 15 to 20 nm cit-AuNP seems to involve reduction in inflammatory cytokines concentration, increase in anti-inflammatory cytokines concentration, reduction in cyclooxygenase type 2, in great part by modulating the expression/activity of transcription factors, mainly the nuclear transcription factor kappa B (NF-kB) [33–38]. It was also reported 20 nm cit-AuNP reduce oxidative stress, in part by reducing the inducible nitric oxygen synthase (iNOS) expression, and increasing glutathione and antioxidant enzymes activity [34, 35, 37–40]. Together, the above-mentioned pharmacological features of the 20 nm cit-AuNP have largely contributed to their success in treating several different animal models of disease in which inflammation and oxidative stress play important roles, such as, colitis, Alzheimer’s disease, and rheumatoid arthritis [33, 34, 38, 40]. Anti-inflammatory action of 15 to 20 nm cit-AuNP seems to involve reduction in inflammatory cytokines concentration, increase in anti-inflammatory cytokines concentration, reduction in cyclooxygenase type 2, in great part by modulating the expression/activity of transcription factors, mainly the nuclear transcription factor kappa B (NF-kB) [33–38]. It was also reported 20 nm cit-AuNP reduce oxidative stress, in part by reducing the inducible nitric oxygen synthase (iNOS) expression, and increasing glutathione and antioxidant enzymes activity [34, 35, 37–40]. Anti-inflammatory action of 15 to 20 nm cit-AuNP seems to involve reduction in inflammatory cytokines concentration, increase in anti-inflammatory cytokines concentration, reduction in cyclooxygenase type 2, in great part by modulating the expression/activity of transcription factors, mainly the nuclear transcription factor kappa B (NF-kB) [33–38]. It was also reported 20 nm cit-AuNP reduce oxidative stress, in part by reducing the inducible nitric oxygen synthase (iNOS) expression, and increasing glutathione and antioxidant enzymes activity [34, 35, 37–40]. Together, the above-mentioned pharmacological features of the 20 nm cit-AuNP have largely contributed to their success in treating several different animal models of disease in which inflammation and oxidative stress play important roles, such as, colitis, Alzheimer’s disease, and rheumatoid arthritis [33, 34, 38, 40]. Concomitantly injected in mice with antibiotic treatment, 21 nm cit-AuNP showed both reduced mortality and systemic inflammatory parameters in mice with sepsis [41]. However, nothing is known regarding the effect of 20 nm cit-AuNP treatment in the sepsis induced-inflammation in brain of mice. Once the BBB is compromised, we aim to test whether 20 nm cit-AuNP can alleviate the acute changes caused by sepsis in brain of mice, with focus on inflammation.

**Results**

**Gold nanoparticles**

Concentration of the colloidal cit-AuNP solution provided was $6.5 \times 10^{11}$ nanoparticles/mL in Milli-Q H$_2$O, the average size was 20.1 ± 2.4 nm, and zeta potential of –26.1 mV. This zeta potential indicates high stability in solution.
Leukocyte and platelet adhesion in pial microvessels
Increase in leukocyte and platelet adhesion in pial microvessels was observed 6 h after sepsis induction in mice compared to both the intact and sham groups (Fig. 1a and b). Mice treated with cit-AuNP 2 h after sepsis induction did not show enhanced leukocyte and platelet adhesion in pial microvessels (Fig. 1a and b). The same result was observed in mice treated with cit-AuNP 4 h after sepsis induction (Fig. 1c and b). Once we did not observe differences in leukocyte and platelet adhesion in cerebral microvessels of mice from the intact and sham groups, next experiments had the sham-operated mice as the only control group.

Evans blue extravasation in brain
Sepsis enhanced the EB extravasation in brain of mice observed 6 h after induction compared to the sham group (Fig. 1e). Cit-AuNP injected 2 h after induction of sepsis avoided increase in Evans blue blood vessels permeation (Fig. 1e).

Cytokines concentration in brain
TNFα, IL-6, IFNγ, IL-1β and IL-10 were measured in brain of mice 6 h after induction of sepsis. We observed none of those cytokines were changed in brain of mice with sepsis compared to the sham group at that time (Fig. 2). Cit-AuNP treatment performed 2 h after induction of sepsis reduced cerebral TNFα concentration, but not other cytokines, compared to mice with sepsis treated with saline (Fig. 2).

By doing real time PCR, we observed sepsis caused increase in TNFα mRNA in brain 6 h after induction, and Cit-AuNP treatment performed 2 h after induction of sepsis reduced TNF mRNA levels in the cerebral tissue (Fig. 3).

Cell adhesion molecules expression
ICAM-1 and L-selectin were measured in circulating polymorphonuclear (PMN) leukocytes 6 h after induction of sepsis in mice. Sepsis increased ICAM-1, but not L-selectin, expression in circulating PMN leukocytes compared to the sham group (Fig. 4a and b). Cit-AuNP treatment performed 2 h after induction of sepsis reduced the ICAM-1 and did not change de L-selectin expression in PMN leukocytes compared to saline-treated mice (Fig. 4a and b).

ICAM-1 expression was measured in cerebral microvessels of mice 6 h after sepsis induction as well. Enhanced ICAM-1 expression was observed in cerebral microvessels of mice with sepsis compared to sham-operated mice (Fig. 5). Cit-AuNP treatment performed 2 h after induction of sepsis reduced ICAM-1 expression in cerebral microvessels of mice compared to saline-treated mice (Fig. 5).

Transcription factors and transcription factors related-proteins expression in brain
Transcription factors and related proteins were measured in brain of mice 6 h after induction of sepsis. We observed enhanced expression of phosphorylated IkBα, but not total IkBα, in brain of mice with sepsis compared to the sham-operated mice (Fig. 6). Mice with sepsis previously treated with cit-AuNP did not show enhanced phosphorylated IkBα expression in brain compared to the sham group (Fig. 6). Cit-AuNP treatment did not change the total IkBα expression in brain of mice with sepsis (Fig. 6).

Regarding to the transcription factors AP1 and HIF-1α, sepsis did not change their expression in brain of mice [see Additional file 1]. Cit-AuNP treatment performed 2 h after sepsis induction did not change the AP1 and HIF-1α expressions in brain of mice as well [see Additional file 1].

Survival curve
Mice with or without sepsis (sham group) were treated with saline or cit-AuNP and followed for ten days in order to measure the survival rate. We observed that all mice with sepsis did not survive longer than five days and cit-AuNP did not change the survival rate compared to saline-treated mice (Fig. 7a). Conversely, all sham-operated mice survived during the whole observation time (Fig. 7a).

When cit-AuNP or saline was combined with the antibiotic treatment regimen (imipenem/cilastatin), 17% of survival was observed in mice with sepsis after 10 days of observation in both groups (Fig. 7b). Thus, no significant difference was observed when cit-AuNP was combined with antibiotics compared to saline and antibiotics treatment regimen.

Discussion
In this study we observed 20 nm cit-AuNP treatment reduced leukocyte and platelet adhesion in pial vessels of mice with sepsis, alleviated BBB failure, and, in parallel, reduced TNFα concentration and phosphorylated IkB expression in the brain parenchyma, ICAM-1 expression in both PMN leukocytes and cerebral blood vessels, and did not interfere with the effect of imipenem/cilastatin on the survival rate of mice with sepsis.

In an elegant in vitro experiment, it was demonstrated that an experimental cytokine mixture, which mimicked plasma obtained from patients with severe sepsis, led to enhanced human leukocytes adhesion to human
cerebrovascular endothelial cells (hCMEC/D3) [42]. Similarly, increased leukocyte and platelet adhesion to cerebral vessels is a common finding in animal models of SAE [43–47]. Corroborating those results, we observed sepsis increased both leukocyte and platelet adhesion to pial vessels of mice. Regarding to the effect of 20 nm cit-AuNP on the leukocyte adhesion, we demonstrated in a previous study enhanced leukocyte adhesion in mesentery microvessels of rats submitted to laparotomy, and previous treatment with 20 nm cit-AuNP prevented that leukocyte-endothelial cells interaction [32]. Now, we report that 20 nm cit-AuNP reduces not only leukocyte adhesion but also platelet adhesion in pial vessels of mice 6 h after induction of sepsis. Of importance, reduction of leukocyte and platelet adhesion were observed in two different treatment protocols: cit-AuNP injected either 2 h

![Fig. 1](image)

**Fig. 1** Effect of citrate-covered gold nanoparticles (cit-AuNP) on leukocyte and platelet adhesion and blood brain barrier. Twenty nanometers cit-AuNP or saline was injected intravenously (IV) 2 (a, b, and e) or 4 h (c and d) after induction of sepsis or the sham-operated procedure in mice. Intact group was submitted to no surgery or treatment. Leukocyte (a and c) and platelet (b and d) adhesion to pial microvessels and BBB permeability assay (e) were performed 6 h after induction of sepsis. Sepsis led to enhanced leukocyte and platelet adhesion to pial vessels, and cit-AuNP treatment reduced those parameters. Sepsis also led to BBB failure, but that BBB compromising was not observed in mice previously treated with cit-AuNP. *P < 0.05 vs. Intact; #P < 0.05 vs. Sham + saline; &P < 0.05 vs. sepsis + saline. ANOVA followed by Tukey’s test was used for comparison when more than two groups were assayed, and unpaired t test was used for comparison between two groups. Five to ten animals per group were used. n.s., not significant
or 4 h after induction of sepsis. This implies in a larger therapeutic window. Leukocyte adhesion is commonly accompanied by platelet adhesion during an inflammatory insult. CAMs are greatly responsible for that interaction [48]. Along with reduction in leukocyte adhesion, it is usual to occur lower platelet adhesion once they interact each other. Several studies show parallel reduction in both leukocyte and platelet adhesion to microvessels after a therapeutic intervention [49–51]. Apart from the study we published few years ago [32], no reports have investigated the effect of gold nanoparticles on the leukocyte adhesion so far and even less on the platelet adhesion under any circumstance. Despite of that, it has long been known the anti-adhesive leukocyte-endothelial cell property of molecular gold. It was showed gold sodium thiomalate and auranofin impaired interleukin 1 beta (IL-1β)-induced human umbilical vein endothelial cells (HUVEC) to bind PMN cells by diminishing E-selectin and/or ICAM-1 expression, in vitro [52]. Not only PMN leukocyte adhesion, but also PMN leukocyte migration is inhibited by gold ions, as demonstrated in [53]. This anti-adhesive property of molecular gold reducing the leukocyte-endothelial cell interaction helps to understand now the past clinical use of gold compounds in the treatment of inflammatory disease, mainly rheumatoid arthritis [54, 55]. Reduction of migration induced by gold nanoparticles is also observed in several other cell types besides PMN leukocytes, like endothelial cells or cancer cells [56–58], what makes gold nanoparticles potential treatment not only for inflammatory conditions but also other diseases, as cancer.

![Fig. 2](image1.png)  
**Fig. 2** Effect of citrate-covered gold nanoparticles (cit-AuNP) on cerebral cytokines in mice with sepsis. Twenty nanometers cit-AuNP or saline was injected intravenously (IV) 2 h after induction of sepsis or the sham-operated procedure in mice. No significant change in tumor necrosis factor alpha (TNFα) (a), interleukin 6 (IL-6) (b), interferon gamma (IFNγ) (c), IL-1β (d), or IL-10 (e) was noticed in the cerebral tissue 6 h after induction of sepsis. Cit-AuNP treatment reduced TNFα concentration, but not other cytokines.* P < 0.05 vs. Sepsis + saline. ANOVA followed by Tukey’s test was used for comparison among groups. Five to six animals per group were used.

![Fig. 3](image2.png)  
**Fig. 3** Effect of citrate-covered gold nanoparticles (cit-AuNP) on TNFα mRNA in brain of mice with sepsis. Twenty nanometers cit-AuNP or saline was injected intravenously (IV) 2 h after induction of sepsis or the sham-operated procedure in mice. Enhanced TNFα mRNA expression was observed in the cerebral tissue 6 h after induction of sepsis, and cit-AuNP treatment reduced it. * P < 0.05 vs. sham; # P < 0.05 vs. Sepsis + saline. ANOVA followed by Tukey’s test was used for comparison among groups. Five to six animals per group were used.
BBB damage in patients with sepsis was observed using different strategies: (i) post-mortem [59]; (ii) after incubating hCMEC/D3 cells, as a model of BBB, in presence of serum from septic patients [60]; and (iii) indirectly, by measuring plasma S100B, a marker of BBB lesion [61]. BBB failure is often reported in animal models of sepsis as well [62–64]. Corroborating those reports, we observed enhanced BBB permeability in mice 6 h after induction of sepsis. Furthermore, we demonstrated besides reducing leukocyte and platelet adhesion to pial vessels, 20 nm cit-AuNP treatment prevented that BBB failure. This is the first study to show the anti-edema effect of 20 nm cit-AuNP. Prolonged leukocytes and endothelial cells interaction can greatly increase blood vessels permeability [65]. Then, reducing leukocyte adhesion to pial vessels may have accounted for the diminished BBB failure we observed after cit-AuNP treatment. Effect of 20 nm cit-AuNP reducing vascular leakage may be important in other conditions where edema greatly contributes to disease phenotype, like in ischemic stroke and cerebral trauma. Additional studies can address that hypothesis.

According to our results, the therapeutic effect of 20 nm cit-AuNP reducing leukocyte and platelet adhesion to pial vessels and edema in brain of mice 6 h after induction of sepsis may come at least in part from its action reducing TNFα concentration in brain and, in a larger extension, by diminishing the ICAM-1 expression both in leukocytes and cerebral blood vessels. Studies show TNFα concentration in brain either increases or does not change after induction of sepsis in mice. It was reported moderate increase in TNFα concentration in brain of mice 6 h after induction of sepsis and that increase was
Fig. 5  Effect of citrate-covered gold nanoparticles (cit-AuNP) on ICAM-1 in cerebral vessels of mice with sepsis. Twenty nanometers cit-AuNP or saline was injected intravenously (IV) 2 h after induction of sepsis or the sham-operated procedure in mice. Representative photos of the ICAM-1 expression in cerebral blood vessels (black arrows) from a negative control (NC) (in which no anti-ICAM-1 antibody was added in the assay) (a), sham-operated mice treated with saline (b), mice with sepsis treated with saline (c), and mice with sepsis treated with cit-AuNP (d). e Quantification of the ICAM-1 expression in the cerebral blood vessels. Enhanced ICAM-1 expression in cerebral blood vessels was noticed 6 h after induction of sepsis, and cit-AuNP treatment reduced it. * P < 0.05 vs. NC; † P < 0.05 vs. Sham + saline; ‡ P < 0.05 vs. Sepsis + saline. ANOVA followed by Tukey’s test was used for comparison among groups. Five to six animals per group were used. Bar, 10 µm
higher 12 h up to 7 days after induction [66]. Other reports showed increase in TNFα concentration 3 h and 4 h, respectively, but not 24 h after LPS injection in mice [67, 68]. On the other hand, another study showed no increase in TNFα concentration 0.5, 1, 2, 4, and 24 h in brain of mice after LPS injection [69]. Here we demonstrated a great increase in TNFα mRNA expression and a slight and not significant increase in TNFα protein concentration in brain of mice 6 h after induction of sepsis, and 20 nm cit-AuNP treatment reduced both TNFα protein and mRNA levels. This is the first time it is reported decrease in TNFα levels in brain of mice after 20 nm cit-AuNP treatment, although the effect of 20 nm cit-AuNP reducing TNFα concentration in other tissues was previously demonstrated by others. In fact, it was observed reduced TNFα circulatory concentration after concomitant 21 nm cit-AuNP and antibiotic injection 18 h after induction of sepsis in mice compared to mice with sepsis that received only antibiotic treatment [41]. Twenty nanometers cit-AuNP intraperitoneally injected for 20 days reduced TNFα concentration in serum of arthritic rats [34]. Thirty nanometers cit-AuNP topically applied reduced the enhanced TNFα concentration in aqueous humor of rats 24 h after LPS-induced uveitis compared to saline-treated rats [70]. Not only protein concentration, but also TNF mRNA are reduced after cit-AuNP treatment in liver and fatty tissue of mice fed high fat diet (HFD) for 28 days and treated for nine weeks with 21 nm cit-AuNP compared to HFD mice that received only vehicle [71].

CAMs are of fundamental importance to leukocyte and endothelial cell interaction and participate in all steps of the diapedesis process, i.e., rolling, crawling, firm adhesion, and migration. Of those, ICAM-1 plays a critical role for the leukocyte adhesion to endothelial cells in several tissues, including in cerebral blood vessels of mice after induction of sepsis [72], or in an in vitro model of interaction of human PMN and human cerebrovascular endothelial cells, in which PMN were previously stimulated with plasma from severe sepsis patients [42]. Similarly, we observed enhanced ICAM-1 expression in cerebral blood vessels of mice 6 h after induction of sepsis. Additionally, increase in ICAM-1 expression in PMN was also demonstrated. Enhanced ICAM-1 expression in pial vessels induced by sepsis may explain the increase in leukocyte adhesion in our model. Different from the adhesive role of ICAM-1 in blood vessels, enhanced ICAM-1 expression on PMN leukocytes we demonstrated 6 h after induction of sepsis probably contributed for the disease progression. Our results also showed 20 nm cit-AuNP reduced ICAM-1 expression...
both in leukocytes and cerebral blood vessels. In this context, it was demonstrated gold nanoparticles reduce TNF-α-induced CAM in both human umbilical vein endothelial cells and aortic endothelial cells by increasing their ubiquitination, i.e., degradation [75]. The same seems to happen in PMN leukocytes, but probably not in cerebral endothelial cells, once we observed reduction in ICAM-1 expression in circulating PMN 4 h after intravenous treatment with cit-AuNP but not appreciable amount of cit-AuNP in the cerebral tissue of cit-AuNP-treated mice [see Additional file 1]. Cit-AuNP would be expected to be seen in the cerebral tissue to explain a direct action of cit-AuNP enhancing the ICAM-1 degradation in endothelial cells. Thus, 20 nm cit-AuNP probably acted indirectly on cerebral endothelial cells reducing their inflammatory profile after reducing activation of circulatory PMN leukocytes. In fact, activation of endothelial cells by circulating leukocytes have been reported for a long time [76–78]. Additionally, we observed increase in phosphorylated IκBα expression in brain of mice 6 h after induction of sepsis, and 20 nm cit-AuNP treatment reduced the enhanced expression of that phosphorylated transcription modulator. IκBα phosphorylation allows NF-κB migrates to the nucleus and bind to the DNA to transcribe pro-inflammatory molecules [79]. Then, cit-AuNP probably also indirectly mediated reduction in phosphorylated IκBα, leading to lower NF-κB migration to the nucleus and lowering expression of molecules that participate in the inflammatory process, such as ICAM-1 and TNFα. As we commented above, we observed both lower TNFα concentration in brain and expression of ICAM-1 in circulating PMN and pial vessels of mice with sepsis previously treated with cit-AuNP.

Regarding to the effect of 20 nm cit-AuNP on the survival rate of animal with sepsis, we did not observe change of it, i.e., no mice survived after five days of sepsis induction both after cit-AuNP or saline treatment. The same way, when 20 nm cit-AuNP and antibiotic (imipenem/cilastatin) were injected in combination, gold nanoparticles did not interfere with the survival rate after 10 days of observation, i.e., no significant difference was observed compared to the group treated only with the antibiotic regimen. No interference in the antibiotic effect on the survival rate is an advantage of 20 nm cit-AuNP concomitant treatment once they would probably be used together in a sepsis patient. On the other hand, slight improvement in the survival rate was observed when 21 nm cit-AuNP was combined with imipenem/cilastatin treatment, however, the observation period they used was 4 days while we observed mice 10 days after induction of sepsis [41]. Thus, there is a possibility that after ten days of observation, that difference reported could not be seen anymore.

**Conclusions**

In the present study, we show for the first time the beneficial effect of 20 nm cit-AuNP in reducing brain inflammation induced by sepsis. Besides, 20 nm cit-AuNP did not interfere with the antibiotic effect on the survival rate of mice with sepsis, what makes 20 nm cit-AuNP a potential candidate to be used as adjuvant along with antibiotics in the treatment of sepsis, in order to avoid SAE.
Methods

Gold nanoparticles
Gold nanoparticles used in this study were ordered from the Nitparticles Company (catalog number #510,006,160, Zaragoza, Spain). Cit-AuNP were diluted in Milli-Q H2O. Citrate was used as a reducing agent to form and stabilize the gold nanoparticles in solution, avoiding aggregates formation and, then, changes in nanoparticles diameter, as described in [80]. Cit-AuNP stability is one year in fridge, according to the manufacturer.

Animals
Seven-week-old specific-pathogen-free (SPF) female C57BL/6 mice (18–22 g body weight) were ordered from the Medical School Animal Facility Network at the University of Sao Paulo (USP). They were housed in the vivarium of the Department of Pharmacology in the Institute of Biomedical Sciences (IBS) until use. Mice were housed in a 12 h/12 h light-dark cycle, controlled room temperature (22 to 24 °C) and humidity (30 to 70%). They were fed chow and water ad libitum until use. All efforts were made to minimize suffering and to reduce the number of animals used.

Sepsis induced by cecal ligation and puncture
Sepsis was induced in eight- to ten-week-old mice by doing the cecal ligation and puncture (CLP) method, according to [81]. In brief, mice were anesthetized with inhaled 2% isoflurane (Isoforine®, Cristalia, Itapira, SP, Brazil), abdominal upper midline incision was performed, and cecum exteriorized. Cecum was ligated 1 mm distal from the ileocecal valve using a 6-0 nylon thread and punctured twice (middle and distally) using a 21G needle. Few feces extravasated. Cecum was gently put back the abdominal cavity and muscle and skin individually closed using a 6–0 nylon suture. Mice were rehydrated by subcutaneously injecting 1 mL saline. Aseptic material was used for the procedure that lasted about 15 min. Mice were observed until recovering from anesthesia and experiments were performed 6 h after induction of sepsis. Similar protocol was done in sham animals, but no ligation and puncture were carried out. One intact group was added in which no surgery was done.

Gold nanoparticle treatment
Two hours after induction of sepsis, mice were anesthetized with inhaled 2% isoflurane (Isoforine®) and a small vertical incision performed in the mid inner thigh to intravenously (IV) inject $2.9 \times 10^{11}$ cit-AuNP (150 µL volume). An additional group of mice was treated with cit-AuNP 4 h after induction of sepsis the same dose and site of injection described above. We previously demonstrated that a similar dose of cit-AuNP IV injected reduced the enhanced surgery-induced leukocyte adhesion in mesentery vessels of rats [32]. Similar protocols were used to inject saline in both mice with sepsis and the sham group.

Mice preparation for pial vessels observation
Leukocytes and platelet adhesion to pial vessels were studied by fluorescence intravital microscopy, as previously described [82]. Briefly, six hours after induction of sepsis or the sham-operated procedure, mice were anesthetized with intraperitoneal (IP) ketamine and xylazine (100 mg/kg and 10 mg/kg body weight, respectively) and a polyethylene microtubing (PE/1, Scientific commodities, Lake Havasu City, AZ, USA) was fixed in the left femoral vein to allowing IV injection of 0.02% 6G-rhodamine (Sigma-Aldrich, St. Louis, MN, USA), labeled platelets and supplemental anesthesia. After craniotomy, exposed brain tissue was immersed in an artificial cerebrospinal fluid and cerebral vessels were observed through the dura mater with an upright fluorescence microscope (DM LFS, Leica, Wetzlar, Germany), using a 40x water immersion lens. Pial venules (20 to 50 µm diameter, 100 µm long) were randomly chosen for observation.

Platelets isolation and labelling
Approximately $100 \times 10^6$ platelets were isolated from a healthy donor mouse, labeled (in green) ex vivo with 90 µM carboxyfluorescein diacetate succinimidyl ester (carboxyfluorescein diacetate, succinimidyl ester, mixed isomers, ThermoFisher Scientific, Waltham, MA, USA)—this extracorporeal staining produces minimal activation of platelets—according to the protocol described in [83], and injected in a recipient mice with or without sepsis (sham or intact groups) through the left femoral vein just before observation. Following platelets injection, 100 µL of 0.02% rhodamine 6G was slowly injected (for 5 min) to fluorescently label (in red) circulating leukocytes. Adhesion leukocytes and platelets were defined as cells remaining stationary within venules for 30 seconds. Cell adhesion data are expressed as number of cells per millimeter squared of venular surface, calculated from venular diameter and length, assuming cylindrical geometry.

Blood brain barrier permeability assay
Permeability of BBB was assessed using the Evans blue (EB) extravasation method, according to the protocol described in [82]. Shortly, 2% EB (Sigma-Aldrich) solution was prepared and injected (4 mL/kg) into the femoral vein just after induction of sepsis or the sham-operated procedure. Two hours later cit-AuNP or saline were injected into the contralateral femoral vein as described above, and assay was carried out 6 h
after induction of sepsis. For that, blood (0.4 mL) was collected from the inferior vena cava, and mouse was transcardially perfused with phosphate-buffered saline (PBS) (100 mm Hg) for 5 mins. Brain was removed and separated from the dura mater and cerebellum. Cerebrum was divided into hemispheres, each of which was homogenized and sonicated in 1 mL of 50% trichloroacetic acid (Sigma-Aldrich), and centrifuged at 12,100x g for 20 mins. The supernatant was diluted with ethanol and the concentrations of EB in brain tissue and plasma were measured using a fluorescence spectrophotometer (FLUOstar Optima microplate reader; BMG LABTECH, Inc, Ortenberg, Germany). The BBB permeability was quantified by dividing tissue EB concentration (µg/g brain weight) by the plasma EB concentration (µg/g).

**Brain and blood collect**

Six hours after induction of sepsis or the sham-operated procedure, median longitudinal laparotomy was performed in previously anesthetized mice (100 mg/kg ketamine and 10 mg/kg xylazine I.P. injected), blood collected from the vena cava into a dextrose-citrate solution-containing tube (1:10, vol:vol) (Sigma-Aldrich), which was used to prevent blood clotting, and prepared for measuring cell adhesion molecules (CAMs) expression in leukocytes by flow cytometry. Mice were then transcardially perfused with PBS (100 mmHg) for about 5 mins, brain was harvested, divided into hemispheres, the right one used to measure intercellular adhesion molecule 1 (ICAM-1) by immunohistochemistry, and the left one quickly frozen, and kept in −80°C freezer until use, in order to measure cytokines by enzyme-linked immunosorbent assay (ELISA), and phosphorylated or total inhibitor of kappa B alpha (IκBα), activator protein 1 (AP-1), and hypoxia inducible factor 1 alpha (HIF-1α) by western blotting. All those techniques are described ahead.

**Cytokines measurement in brain**

Frozen brain was powered and homogenized in lysis buffer (10% RIPA buffer, Merk Millipore, MA, USA), added 1 mM phenylmethylsulfonyl fluoride (PMSF) (Amresco, Solon, OH, USA), 10 mM sodium orthovanadate (Sigma-Aldrich), 100 mM sodium fluoride (LabSynth, Diadema, SP, Brazil), 10 mM sodium pyrophosphate (Sigma-Aldrich), and 0.2% protease inhibitor (P8340, Sigma-Aldrich), for 30 min at 4°C, and centrifuged (15,000x g, 4°C, 20 min) to obtain supernatant. Total proteins were quantified in supernatant (PierceTM BCA Protein Assay Kit, ThermoFisher Scientific), and interferon gamma (IFN-γ) (Sigma-Aldrich), IL-1β, IL-6, TNFα, (Elabscience, Houston, TX, USA) and IL-10 (Abcam, Cambridge, MA, USA) were measured by ELISA, according to the manufactures instructions. Results are presented as cytokine concentration per mg of protein.

**Real time PCR**

Total ribonucleic acid (RNA) was isolated from frozen brains using TRizol® Reagent according to the manufacturer’s instructions. TNF-α messenger RNA (mRNA) was measured by real time quantitative polymerase chain reaction (qPCR) using GoTaq qPCR Master mix (Promega, Madison, WI, USA). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control. qPCR reactions were performed, recorded, and analyzed using the Corbett research system (Corbett Life Sciences, Sydney, Australia). The conditions for qPCR were as follows: 95°C for 20 s, 40 cycles of 95°C for 3 s and 60°C for 30 s. Cycle threshold (Ct) values obtained for TNF-α wererelated to GAPDH (ΔCt) and converted to the linear form using the term 2−ΔΔCt as a value directly proportional to the number of copies of complementary DNA and the initial quantity of mRNA. Primer sequences: TNF-α, F: ATG AGC ACA GAA AGC ATG ATC; R: TAC AGG CTT GTCA CTG AA T (275pb) (NM_013693.2); GAPDH, F: GGG CAG CCC AGA ACA TCA T; R: CCG TTC AGC TCT GGG ATG AC (76 bp) (NM_017008.4).

**Flow cytometry**

After blood collect, erythrocytes were lysed by using a commercially available hypotonic lysis solution (BD FACSTM, BD Biosciences, San Jose, CA, USA), leukocytes obtained after centrifugation (600x g, 10 mins) were resuspended in Hank’s balanced salt solution (HBSS) (Thermo Fisher Scientific) added 0.1% bovine serum albumin (BSA, Sigma-Aldrich), and incubated with anti-L-selectin fluorescein-conjugated (10 µL/10⁶ cells, Bio-Techne, Minneapolis, MN, USA) or anti-ICAM-1 Alexa Fluor® 488-conjugated monoclonal antibody (1 µg, Santa Cruz Biotechnology, Dallas, TX, USA) for 20 min, at 4°C. Negative control was not added any antibody. Leukocytes were washed with HBSS plus BSA buffer, fixed in 4% paraformaldehyde for 12 h later in a flow cytometer (BD Accuri C6, BD Biosciences, San Jose, CA, USA). Ten thousand cells were counted per sample.

**Immunohistochemistry**

Brains collected 6 h after induction of sepsis were immersed in a 4% paraformaldehyde solution (Lab-synth) for 24 h, following immersion in 30% sucrose solution (Labsynth) for additional 24 h, were embedded.
in O.C.T freezing medium (Sakura, Alphen aan den Rijn, Holanda) and kept in −80°C freezer until use. Eight micrometers sections were obtained in cryostat (Leica, CM1850, Leica Microsystems, Wetzlar, Germany), endogenous peroxidase blocked using 0.3% hydrogen peroxide solution (prepared in metanol) for 10 min, and washed in 1x PBS solution added 0.3% Tween 20 (Sigma-Aldrich). Nonspecific protein-binding sites were blocked using 3% BSA (Sigma-Aldrich) for 30 min, at room temperature. Sections were then incubated with anti-ICAM-1 monoclonal primary antibody (1:1000, vol:vol, Abcam) for 2 h in a humidity chamber. As negative control, no primary antibody was added to some sections. Horseradish peroxidase (HRP)-conjugated secondary antibody (1:1000, vol:vol, Santa Cruz Biotechnology) was added to the sections for 1 h, except for some sections, used as an additional negative control in which no secondary antibody was added (just the primary antibody was used). Labeling was visualized after incubation with a Peroxidase Substrate kit (Vector Laboratories, CA, USA) for 5 to 15 min. Entellan® (Merck, EUA) was used to mount the glass slides, images were obtained using optical microscopy (Leica DMLFS, DFC300 FX, Leica Microsystems), a 20X objective for observation (HCX PL FLUOTAR, Leica Microsystems), a software for capturing (LEICA IM50, Leica Microsystems), and analysis were carried out using the software Image J (Wayne Rasband, National Institute of Health, USA). Results are presented as arbitrary units.

**Western blotting**

Frozen brain was powered, homogenized, and supernatant obtained the same way as described in the "Cytokines measurement in brain" Section. Total proteins were quantified in supernatant (PierceTM BCA Protein Assay Kit, ThermoFisher Scientific), 50 µg of proteins were loaded on a 10% polyacrylamide gel (Sigma-Aldrich) and transferred to a polyvinylidene fluoride membrane (PVDF) (GE Healthcare, Little Chalfant, Buckinghamshire, United Kingdom) for 40 min, 80V and 4 °C. Nonspecific binding was blocked using 3% BSA in tween Tris buffered saline (TTBS) buffer (pH 7.6) (LabSynth) for 1.5 h, at room temperature. Membranes were incubated overnight with anti-phosphorylated IkB (phospho-IkB) or anti-IkB primary antibodies (1:350 and 1:1000, vol:vol, respectively, Cell Signaling Technology, MA, USA) at 4 °C. Actin labeling (1:200, vol:vol, Santa Cruz Biotechnology) after membrane stripping (Restore™ Western Blot Stripping Buffer, Thermo Fisher Scientific) was used as loading control and results were related to it. HRP-conjugated secondary antibody (1:2500, vol:vol, Santa Cruz Biotechnology) was put in contact with the membranes for 1.5 h, at room temperature, blotting was visualized after incubation with a quimoluminescence solution (Pierce® ECL Western Blotting Substrate, Thermo Fisher Scientific), and images captured using a luminescence reader device (Carestream Molecular Imaging, Gel Logic 2200 PRO, Carestream Health, NY, EUA). Blotting density was quantified using the software Image J (Wayne Rasband), and expressed as arbitrary units. Protocol for AP-1 and HIF-1α detection is described in the supplemental material [see Additional file 1].

**Survival rate**

Mice were daily followed for 10 days to measure the survival rate after induction of sepsis. Cit-AuNP or saline was injected twice, 2 and 24 h after induction of sepsis, the same protocol and dose described in the "Gold nanoparticle treatment" Section. A group of mice was concomitantly IV treated with an antibiotic regimen composed of imipenem and cilastatin (0.3 mg and 0.6 mg per animal, respectively) (Sigma-Aldrich) injected twice a day for three days (through the femoral vein), starting 2 h after induction of sepsis and at 12 h intervals afterwards, to determine whether any drug interaction would occur compared to a group only treated with imipenem and cilastatin. This antibiotic regimen was previously described in [84], and slightly modified. Alternate femoral veins were used every treatment time.

**Statistical analysis**

All results are expressed as mean±standard error of the mean (SEM). To verify whether there was difference between groups, unpaired t-test, analysis of variance (ANOVA) followed by Tukey test, or Log-rank (Mantel-Cox) test were used. All analyses were performed using the Prism 5 software (GraphPad Software, Inc.), and statistical significance was set as P<0.05.

**Supplementary Information**

The online version contains supplementary material available at [https://doi.org/10.1186/s12951-021-00796-6](https://doi.org/10.1186/s12951-021-00796-6).
Abbreviations

ANOVA: Analysis of variance; AP-1: Activator protein 1; a.u.: Arbitrary units; BBB: Blood brain barrier; BSA: Bovine serum albumin; CAM: Cell adhesion molecules; CD14: Cluster of differentiation 14; CIT-AuNP: Citrate-covered gold nanoparticles; C18: C-18; CVD: Circumventricular organs; CT: Cycle threshold; CVO: Cerebral venous sinuses; EB: Evans blue; EEG: Electroencephalogram; ELISA: Enzyme-linked immunosorbent assay; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; HBSS: Hank’s balanced salt solution; HFD: High fat diet; HIF-1α: Hypoxia inducible factor 1 alpha; HRP: Horseradish peroxidase; HUVEC: Human umbilical vein endothelial cells; IBS: Institute of Biomedical Sciences; ICAM-1: Intercellular cell adhesion molecule 1; IL-1: Interleukin 1; IL-1β: Interleukin 1 beta; IL-10: Interleukin 10; IL-1R: Interleukin 1 receptor; IL-6R: Interleukin 6 receptor; IFN-γ: Interferon gamma; IBS: Institute of Biomedical Sciences; IV: Intravenously; LPS: Lipopolysaccharide; mRNA: Messenger ribonucleic acid; NOS: Nitric oxide; n.s.: Not significant; PBS: Phosphate-buffered saline; Phospho-IκB: Phosphorylated inhibitor of kappa B; PMN: Polymorphonuclear; PMSF: Phenylmethysulfonfluoride; PVDF: Polyvinylidene fluoride; qPCR: quantitative polymerase chain reaction; RNA: Ribonucleic acid; ROS: Reactive oxygen species; SAE: Sepsis associated-encephalopathy; SEM: Standard error of the mean; SPF: Specific-pathogen-free; TLR4: Toll-like receptor 4; TNFα: Tumor necrosis factor alpha; TUNA: Tumor necrosis factor alpha; TLR: Toll-like receptor; TUNA: Tumor necrosis factor alpha; UCB: University of Sao Paulo; USP: University of Sao Paulo; Wistar Institute of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 1524, ICB, L. sala 205, 2° andar, Butanta, 05508-900 Sao Paulo, Brazil. * Laboratory of Vascular Nanopharmacology, Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 1524, ICB, L. sala 319, 3° andar, Butanta, 05508-900 Sao Paulo, Brazil. 

Acknowledgements

Authors are grateful to MSc. Gisela R. Terçaroli for the technical support provided in the sample preparation for the TEM assay, and to LNInano/CNPEm for the access to the electron microscopy facility and technical support, in the execution of the proposal TEM-27571-F.

Authors’ contribution

DB, JPF, RNS, CE, AM, and SFR performed experiments, collected, and interpreted data. All authors read and approved the final manuscript.

Funding

Authors are grateful for the financial support of FAPESP: grant # 2014/05146-6, and scholarships for the following authors: DB (# 2016/18602-5), JPF (# 2018/12258-6), and SFR (# 2015/04281-0).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

All experimental procedures involving animals performed in this study were previously approved by the Ethics Committee for Animal Use of IBS (called CEUA-ICB), which follows rules determined by the National Council for Experimental Animal Controlling (called CONCEA), from Brazil, and the National Institutes of Health (NIH) guide for the care and use of Laboratory animals, from USA.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 Laboratory of Hypertension, Diabetes and Vascular Biology, Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 1524, ICB, L. sala 205, 2° andar, Butanta, 05508-900 Sao Paulo, Brazil. 
2 Laboratory of Vascular Nanopharmacology, Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Av. Prof. Lineu Prestes, 1524, ICB, L. sala 319, 3° andar, Butanta, 05508-900 Sao Paulo, Brazil.

Received: 4 October 2020 Accepted: 8 February 2021
Published online: 19 February 2021

References

1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: International Guidelines for Management of Sepsis and Septic Shock. Intensive Care Med. 2017;43:304–77.
2. Stevenson EK, Rubenstein AR, Radin GT, Wiener RS, Walkey AJ. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med. 2014;42:625–31.
3. Fleischmann C, Schena A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2016;193:529–72.
4. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsai D, Kielvan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395:200–11.
5. Gots JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ. 2016;353:i5583.
6. Eidelman LA, Putterman D, Putterman C, Sprung CL. The spectrum of septic encephalopathy: definitions, etiologies, and mortalities. JAMA. 1996;275:470–3.
7. Sonneville R, Montmollin E, Poujade J, Garroutte-Orgeas M, Souweine B, Darmon M, et al. Potentially modifiable factors contributing to sepsis-associated encephalopathy. Intensive Care Med. 2017;43:1075–84.
8. Young GB, Bolton CF, Archibald YM, Austin TW, Wells GA. The electroencephalogram in sepsis-associated encephalopathy. J Clin Neurophysiol. 1992;9:145–52.
9. Goffon TE, Young GB. Sepsis-associated encephalopathy. Nat Rev Neurol. 2012;8:557–66.
10. Sprung CL, Peduzzi PN, Shatney CH, Schein RM, Wilson MF, Sheagren JN, et al. Impact of encephalopathy on mortality in the sepsis syndrome. The veterans administration systemic sepsis cooperative study group. Crit Care Med. 1990;18:801–6.
11. Iwashyna TJ, Cooke CR, Wunsch H, Kahn JM. Population burden of long-term survivorship after severe sepsis in older Americans. J Am Geriatr Soc. 2012;60:1070–7.
12. Prescott HC, Langa KM, Liu V, Escobar GJ, Iwashyna TJ. Increased 1-year survivorship after severe sepsis in older Americans. J Am Geriatr Soc. 2012;60:1070–7.
13. Prescott HC, Osterholzer JJ, Langa KM, Angus DC, Iwashyna TJ. Late mortality after sepsis: propensity matched cohort study. BMJ. 2016;353:i2375.
14. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304:1787–94.
15. Yende S, Austin S, Rhodes A, Finfer S, Opal S, Thompson T, et al. Long-term quality of life among survivors of severe sepsis: analyses of two international trials. Crit Care Med. 2016;44:1461–7.
16. Adam N, Kandelman S, Mantz J, Chretien F, Sharshar T. Sepsis-induced brain dysfunction. Expert Rev Anti Infect Ther. 2013;11:211–21.
17. Cooper KE. The neurobiology of fever: thoughts on recent developments. Annu Rev Neurosci. 1987;10:297–324.
18. Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev. 1988;12:123–37.
19. Kent S, Blithé RM, Kelley KW, Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol Sci. 1992;13:24–8.
20. Lacroix S, Feinstein D, Rivest S. The bacterial endotoxin lipopolysaccharide has the ability to target the brain in upregulating its membrane CD14 receptor within specific cellular populations. Brain Pathol. 1998;8:625–40.
21. Kontras JP, Vigue S, Macklerova L, Bristow A, Blomqvist A. Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J Comp Neurol. 2004;472:113–29.
22. Rivest S. Molecular insights on the cerebral innate immune system. Brain Behav Immun. 2005;19:113–9.
23. Korsman JP, Kelley K, Dantzer R. Temporal and spatial relationships between lipopolysaccharide-induced expression of Nos, interleukin-1beta and inducible nitric oxide synthase in rat brain. Neuroscience. 1999;89:535–48.
24. Dantzer R. Cytokine-induced sickness behaviour: a neuroimmunological response to activation of innate immunity. Eur J Pharmacol. 2004;500:399–411.
25. Bluthé RM, Walter V, Parnet P, Layé S, Lestage J, Verrier D, et al. Lipopolysaccharide induces sickness behavior in rats by a vagal mediated mechanism. C R Acad Sci III. 1994;317:499–503.
26. Papadopoulos MC, Lamb FJ, Moss RF, Davies DC, Tighe D, Bennett ED. Fae.
27. Mayhan WG. Effect of lipopolysaccharide on the permeability and reactivity of the cerebral microcirculation: role of inducible nitric oxide synthase. Brain Res. 1998;792:353–7.
28. Bouchard C, Page J, Bédard A, Tremblay P, Vallières L. G protein-coupled receptor 84, a microglia-associated protein expressed in neuroinflammatory conditions. Glia. 2007;55:790–800.
29. Shamsar T, Gray F, de la Grandmaison G, Hopkins NS, Ross E, Dorandeau A, et al. Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. Lancet. 2003;362:1799–805.
30. Dupont S, Garthwaite J. Pathological consequences of inducible nitric oxide synthase expression in hippocampal slice cultures. Neuroscience. 2005;151:115–66.
31. Chuang YC, Tsai JL, Chen SY, Chen YH, Cheng PC, Chang MY, et al. Amelioration of collagen-induced arthritis in rats by nanogold. Arthritis Rheum. 2007;56:544–54.
32. Khan MA, Khan MJ. Nano-gold displayed anti-inflammatory property via NF-κB pathways by suppressing COX-2 activity. Artif Cells Nanomed Biotechnol. 2014;42:497–507.
33. Tsai CY, Shiu AL, Chen SY, Chen YH, Cheng PC, Chang MY, et al. Amelioration of collagen-induced arthritis in rats by nanogold. Arthritis Rheum. 2007;56:544–54.
34. Khan MA, Khan MJ. Nano-gold displayed anti-inflammatory property via NF-κB pathways by suppressing COX-2 activity. Artif Cells Nanomed Biotechnol. 2014;42:497–507.
35. Haupenthal DP, Mendes C, Silveira GB, Bolonheis SM, Kiyohara TO, et al. Myeloperoxidase and septic conditions disrupt sphingolipid homeostasis in murine brain capillaries in vivo and immortalized human brain endothelial cells in vitro. Int J Mol Sci. 2021;22:109.
36. Erikson K, Tuominen H, Vakkala M, Lissansantti JH, Karttunen T, Syrjälä H, et al. Brain tight junction protein expression in sepsis in an autopsy series. Crit Care. 2020;24:385.
37. Goertzner M, Berhnart E, Plastira I, Reichert H, Leopold C, Eichmann TO, et al. Myeloperoxidase and septic conditions disrupt sphingolipid homeostasis in murine brain capillaries in vivo and immortalized human brain endothelial cells in vitro. Int J Mol Sci. 2020;21:1143.
38. Hughes CG, Pandharipande PP, Thompson JL, Chandrasekhar R, Ware LB, Ely EW, et al. Endothelial activation and blood-brain barrier injury as risk factors for delirium in critically ill patients. Crit Care Med. 2016;44:e809-17.
39. Jezonk S, Nguyen T, Connolly L, Doran J, Wang D, et al. Gold nanoparticles sensitize pancreatic cancer cells to gemcitabine. Cell Stress. 2019;3:267–79.
40. Muller AP, Ferreira GK, Pires AJ, Silveira GB, Souza DL, Brandolfo JA, et al. Gold nanoparticles prevent cognitive deficits, oxidative stress and inflammation in a rat model of sporadic dementia of Alzheimer’s type. Mater Sci Eng C Mater Biol Appl. 2017;77:476–83.
41. Taratunmaraat S, Sanghech N, Vu CTB, Palaga T, Ondee T, Surawut S, et al. Gold nanoparticles attenuates bacterial sepsis in cecal ligation and puncture mouse model through the induction of M2 macrophage polarization. BMC Microbiol. 2018;18:85.
42. Blom C, Deller BL, Fraser DD, Patterson EK, Martin CM, Young B, et al. Human severe sepsis cytokine mixture increases β2-integrin-dependent polymorphonuclear leukocyte adhesion to cerebral microvascular endothelial cells in vitro. Crit Care. 2015;19:149.
43. Vachharajani V, Russell JM, Scott KL, Conrad S, Stokes RY, Tallam L, et al. Obesity exacerbates sepsis-induced inflammation and microvascular dysfunction in mouse brain. Microcirculation. 2005;12:183–94.
44. Vachharajani V, Cunningham C, Yozza B, Carson J, Turner J, Vachharajani TJ, McColl C. Adiponectin-deficiency exaggerates sepsis-induced microvascular dysfunction in the mouse brain. Obesity (Silver Spring). 2012;20:498–504.
45. Zhou J, Pavlovic D, Willecke J, Friedel C, Whynot S, Hung O, et al. Activated protein C improves pial microcirculation in experimental endotoxemia in rats. Microvasc Res. 2012;83:276–80.
46. Anandegui G, Zellinski E, Schubert C, Knight D, Craig LA, Winston BW, et al. Targeting inflammatory monocytes in sepsis-associated encephalopathy and long-term cognitive impairment. JCI Insight. 2018;3:e99364.
47. Nvafdo CF, Chakraborty S, Bricachek AL, Jus S, Gambill CA, Wang W, et al. Loss of tissue-nonspecific alkaline phosphatase (TNAP) enzyme activity in cerebral microvesicles is coupled to persistent neuroinflammation and behavioral deficits in late sepsis. Brain Behav Immun. 2020;84:115–31.
48. McEvier RP. Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc Res. 2015;107:331–9.
49. Vowinkel H, Wood KC, Stokes KY, Russell J, Tailor A, Anthoni C, et al. Mechanisms of platelet and leukocyte recruitment in experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2007;293:G154-60.
50. Ishikawa K, Kusaka G, Yamaguchi N, Sekizuka E, Nakadate H, Minamitani H, et al. Platelet and leukocyte adhesion in the microvasculature at the cerebral surface immediately after subarachnoid hemorrhage. Neurosurg. 2009;64:546–54.
51. Rodrigues SF, Almeida-Paula LD, Granger DN. Synergistic effects of high blood cholesterol and hypertension on leukocyte and platelet recruitment in the cerebral microcirculation. Hypertension. 2014;63:747–52.
52. Heimbürger M, Lerner R, Palmblad J. Effects of antiinflammatory drugs on adhesiveness of endothelial cells and neutrophils. Biochem Pharmacol. 1998;56:1661–9.
53. Hujanen ES, Seppä ST, Virtanen K. Polymorphonuclear leukocyte chemotaxis induced by zinc, copper and nickel in vitro. Biochim Biophys Acta. 1995;1245:145–52.
54. Wright V. Oral gold for rheumatoid arthritis. BMJ. 1984;289:858–59.
55. Davis P. Gold therapy in the treatment of rheumatoid arthritis. Can Fam Physician. 1984;34:445–52.
56. Hui L, Zhang Y, Xiong X, Das S, Bhattacharya R, Mukherjee P. Gold nanoparticles sensitize pancreatic cancer cells to gemcitabine. Cell Stress. 2019;3:267–79.
57. Vachharajani V, Russell JM, Scott KL, Conrad S, Stokes RY, Tallam L, et al. Obesity exacerbates sepsis-induced inflammation and microvascular dysfunction in mouse brain. Microcirculation. 2005;12:183–94.
58. Vachharajani V, Cunningham C, Yozza B, Carson J, Turner J, Vachharajani TJ, McColl C. Adiponectin-deficiency exaggerates sepsis-induced microvascular dysfunction in the mouse brain. Obesity (Silver Spring). 2012;20:498–504.
59. Zhou J, Pavlovic D, Willecke J, Friedel C, Whynot S, Hung O, et al. Activated protein C improves pial microcirculation in experimental endotoxemia in rats. Microvasc Res. 2012;83:276–80.
65. Kumar P, Shen Q, Pivetti CD, Lee ES, Wu MH, Yuan SY. Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. Expert Rev Mol Med. 2009;11:e19.

66. Ye B, Tao T, Zhao A, Wen L, He X, Liu Y, et al. Blockade of IL-17A/IL-17R Pathway Protected Mice from Sepsis-Associated Encephalopathy by Inhibition of Microglia Activation. Mediators Inflamm. 2019;2019:8461725.

67. Lee EJ, Han JE, Woo MS, Shin JA, Park EM, Kang JL, et al. Matrix metalloproteinase-8 plays a pivotal role in neuroinflammation by modulating TNF-α activation. J Immunol. 2014;193:2384–93.

68. Hasegawa-Ishii S, Inaba M, Shimada A. Widespread time-dependent changes in tissue cytokine concentrations in brain regions during the acute phase of endotoxemia in mice. Neurotoxicology. 2020;76:67–74.

69. Zhou H, Andonegui G, Wong CHY, Kubes P. Role of endothelial TLR4 for neutrophil recruitment into central nervous system microvessels in systemic inflammation. J Immunol. 2009;183:5244–50.

70. Pereira DV, Petronilho F, Pereira HRS, Vuolo F, Mina F, Possato JC, et al. Effects of gold nanoparticles on endotoxin-induced uveitis in rats. Invest Ophthalmol Vis Sci. 2012;53:8036–41.

71. Chen H, Ng JPM, Tan Y, McGrath K, Bishop DP, Oliver B, et al. Gold nanoparticles improve metabolic profile of mice fed a high-fat diet. J Nanobiotechnology. 2018;16:11.

72. Wang H, Hong Li, Huang JY, Jiang Q, Tao RR, Tan C, et al. P2RX7 sensitizes Mac-1/ICAM-1-dependent leukocyte-endothelial adhesion and promotes neurovascular injury during septic encephalopathy. Cell Res. 2015;25:674–90.

73. Woodfin A, Beyrau M, Voisin MB, Ma B, Whiteford JR, Hordijk PL, et al. ICAM-1-expressing neutrophils exhibit enhanced effector functions in murine models of endotoxemia. Blood. 2016;127:898–907.

74. Murao A, Arif A, Brenner M, Denning NL, Jin H, Takizawa S, et al. Extracellular CIRP and TREM-1 axis promotes ICAM-1-Rho-mediated NETosis in sepsis. PASEB J. 2020. doi:https://doi.org/10.1096/fj.202000482R.

75. Lai TH, Chung CH, Chen BH, Hung CF, Inbaraj BS, Ma MC, et al. Gold Nanoparticles compromise TNF-α-induced endothelial cell adhesion molecule expression through NF-κB and protein degradation pathways and reduce neointima formation in a rat carotid balloon injury model. J Biomed Nanotechnol. 2016;12:2185–201.

76. Kubes P, Kanwar S. Histamine induces leukocyte rolling in post-capillary venules: A P-selectin-mediated event. J Immunol. 1994;152:3570–7.

77. Gautam N, Herwald H, Hedqvist P, Lindbom L. Signaling via beta(2) integrins triggers neutrophil-dependent alteration in endothelial barrier function. J Exp Med. 2000;191:1829–39.

78. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med. 1989;320:365–76.

79. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132:344–62.

80. Turkevich J, Stevenson PC, Hillier J. A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss Faraday Soc. 1951;11:55–75.

81. Singer G, Urakami H, Specian RD, Stokes KY, Granger DG. Platelet recruitment in the murine hepatic microvasculature during experimental sepsis: role of neutrophils. Microcirculation. 2006;13:89–97.

82. Rodrigues SF, Vital SA, Granger DN. Mild hypercholesterolemia blunts the proinflammatory and prothrombotic effects of hypertension on the cerebral microcirculation. J Cereb Blood Flow Metab. 2013;33:483–9.

83. Russell J, Cooper D, Tailor A, Stokes KY, Granger DN. Low venular shear rates promote leukocyte-dependent recruitment of adherent platelets. Am J Physiol Gastrointest Liver Physiol. 2003;284:G123-9.

84. Singer BH, Newstead MW, Zeng X, Cooke CL, Thompson RC, Singer K, et al. Cecal ligation and puncture results in long-term central nervous system myeloid inflammation. PLoS One. 2016;11:e0149136.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.